Niagen Bioscience, Inc. — Director's Dealing 2018

Jan 12, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2018-01-10

Reporting Person: Jaksch Frank L Jr (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-01-10	Common Stock	M	22130	$4.5	Acquired	223687	Direct
2018-01-10	Common Stock	S	22130	$6.52	Disposed	201557	Direct
2018-01-11	Common Stock	M	6249	$4.5	Acquired	207806	Direct
2018-01-11	Common Stock	S	6249	$6.5	Disposed	201557	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-01-10	Employee Stock Options (right to buy)	$4.50	M	22130	Disposed	2018-04-21	Common Stock (22130)	Direct
2018-01-11	Employee Stock Options (right to buy)	$4.50	M	6249	Disposed	2018-04-21	Common Stock (6249)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2075052	Indirect

Footnotes

F1: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted on November 17, 2017. The options exercised and sold were scheduled to expire on April 21, 2018 and Mr. Jaksch sold the shares so that the proceeds can be used to cover the exercise payment and applicable withholding taxes due.

F2: The weighted average sale price for the transaction reported was $6.52, and the range of prices were between $6.50 and $6.58. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.